Raymond James Financial
XFOR icon

Raymond James Financial’s X4 Pharmaceuticals XFOR Stock Holding History

Raymond James Financial’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-66
Closed -$125 – 6808
2025
Q2 		$125 Buy
+66
New +$270 ﹤0.01% 6823

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial's XFOR Position: Q3 2025 in Review

Raymond James Financial sold out of X4 Pharmaceuticals (XFOR) in Q3 2025, closing a stake of 66 shares — an estimated $125 sold.

Raymond James Financial first reported a position in XFOR in Q2 2025 and held it in 1 quarter. The position peaked at $125 in Q2 2025. 42 funds tracked by Wall St. Rank hold XFOR as of Q3 2025.

  • Raymond James Financial reported no remaining X4 Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 66 X4 Pharmaceuticals shares in Q3 2025, an estimated $125.
  • Raymond James Financial first reported a position in X4 Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's X4 Pharmaceuticals position peaked at $125 in Q2 2025.
  • 42 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.